Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

A Phase I, Open-label, Multi-centre, Multiple Ascending Dose Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) in Patients With Acute Myeloid Leukaemia (AML)

A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML). The first three patients to complete a 28 day cycle in the cohort, before the second three patients start treatment.

Inclusion Criteria:

• Newly diagnosed patient.
• Provision of written informed consent.
• De Novo (primary) or Secondary AML.
• Not eligible for intensive induction chemotherapy because of medical, social or psychological reasons.

Exclusion Criteria:

• Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL).
• Patients with blast crisis of chronic myeloid leukaemia.
• Persistent, chronic, clinically significant toxicities from any prior anti- cancer therapy greater than CTCAE Grade 1 (except alopecia).